SER-252 (POZ-apomorphine) in combination with enFuse

July 9, 2026: Serina Therapeutics, Inc. (NYSE: SER) reported completion of sentinel dosing in Cohort 1 of its ongoing SER-252-1b Phase 1b registrational trial of SER-252 (POZ-apomorphine) in adults with advanced Parkinson’s disease and motor fluctuations. After reviewing initial 72-hour safety and tolerability observations from the sentinel dosing group, the independent Safety Monitoring Committee recommended continuing dosing in the remainder of Cohort 1; additional Cohort 1 dosing is underway at sites in the U.S. and Australia.

The randomized, double-blind, placebo-controlled study includes single-ascending-dose cohorts (five cohorts of eight; n=40) and multiple-ascending-dose cohorts (up to three cohorts of sixteen; n=48) and evaluates safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures including MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation is overseen by the Safety Monitoring Committee, and additional sites are planned in South Korea and Taiwan.

Serina now expects to complete Cohort 1 enrollment and dosing ahead of its previously disclosed guidance of end of Q3 2026 (subject to continued trial execution).